AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Saved in:
| Title: | AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. |
|---|---|
| Authors: | Zabludoff SD; AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. sonya.zabludoff@astrazeneca.com, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2008 Sep; Vol. 7 (9), pp. 2955-66. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Print ISSN: 1535-7163 (Print) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 18790776 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zabludoff+SD%22">Zabludoff SD</searchLink>; AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. sonya.zabludoff@astrazeneca.com<br /><searchLink fieldCode="AU" term="%22Deng+C%22">Deng C</searchLink><br /><searchLink fieldCode="AU" term="%22Grondine+MR%22">Grondine MR</searchLink><br /><searchLink fieldCode="AU" term="%22Sheehy+AM%22">Sheehy AM</searchLink><br /><searchLink fieldCode="AU" term="%22Ashwell+S%22">Ashwell S</searchLink><br /><searchLink fieldCode="AU" term="%22Caleb+BL%22">Caleb BL</searchLink><br /><searchLink fieldCode="AU" term="%22Green+S%22">Green S</searchLink><br /><searchLink fieldCode="AU" term="%22Haye+HR%22">Haye HR</searchLink><br /><searchLink fieldCode="AU" term="%22Horn+CL%22">Horn CL</searchLink><br /><searchLink fieldCode="AU" term="%22Janetka+JW%22">Janetka JW</searchLink><br /><searchLink fieldCode="AU" term="%22Liu+D%22">Liu D</searchLink><br /><searchLink fieldCode="AU" term="%22Mouchet+E%22">Mouchet E</searchLink><br /><searchLink fieldCode="AU" term="%22Ready+S%22">Ready S</searchLink><br /><searchLink fieldCode="AU" term="%22Rosenthal+JL%22">Rosenthal JL</searchLink><br /><searchLink fieldCode="AU" term="%22Queva+C%22">Queva C</searchLink><br /><searchLink fieldCode="AU" term="%22Schwartz+GK%22">Schwartz GK</searchLink><br /><searchLink fieldCode="AU" term="%22Taylor+KJ%22">Taylor KJ</searchLink><br /><searchLink fieldCode="AU" term="%22Tse+AN%22">Tse AN</searchLink><br /><searchLink fieldCode="AU" term="%22Walker+GE%22">Walker GE</searchLink><br /><searchLink fieldCode="AU" term="%22White+AM%22">White AM</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2008 Sep; Vol. 7 (9), pp. 2955-66. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Print <i>ISSN: </i>1535-7163 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=18790776 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/1535-7163.MCT-08-0492 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2955 Titles: – TitleFull: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zabludoff SD – PersonEntity: Name: NameFull: Deng C – PersonEntity: Name: NameFull: Grondine MR – PersonEntity: Name: NameFull: Sheehy AM – PersonEntity: Name: NameFull: Ashwell S – PersonEntity: Name: NameFull: Caleb BL – PersonEntity: Name: NameFull: Green S – PersonEntity: Name: NameFull: Haye HR – PersonEntity: Name: NameFull: Horn CL – PersonEntity: Name: NameFull: Janetka JW – PersonEntity: Name: NameFull: Liu D – PersonEntity: Name: NameFull: Mouchet E – PersonEntity: Name: NameFull: Ready S – PersonEntity: Name: NameFull: Rosenthal JL – PersonEntity: Name: NameFull: Queva C – PersonEntity: Name: NameFull: Schwartz GK – PersonEntity: Name: NameFull: Taylor KJ – PersonEntity: Name: NameFull: Tse AN – PersonEntity: Name: NameFull: Walker GE – PersonEntity: Name: NameFull: White AM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2008 Sep Type: published Y: 2008 Identifiers: – Type: issn-print Value: 1535-7163 Numbering: – Type: volume Value: 7 – Type: issue Value: 9 Titles: – TitleFull: Molecular cancer therapeutics Type: main |
| ResultId | 1 |